Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Stigma as a Barrier to HBV Care: Patient and Physician Sharing Session #2

In episode 2 of this ongoing series, listen to a conversation between Robert G. Gish, MD, FAASLD, and patient and advocate, Alan Wang, on approaches to destigmatize HBV infection and remove barriers to care.
Robert G. Gish, MD
Released: April 12, 2021

In episode 2 of an ongoing series of sharing sessions between a physician and patient, Robert Gish, MD, FAASLD, and patient advocate, Alan Wang, discuss stigma as a barrier to optimal HBV care and treatment. The conversation focuses on how stigma affected Alan’s engagement with his care and strategies to overcome stigma as a barrier to HBV care.


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from:
Gilead Sciences, Inc.

Information on this Educational Activity


Robert G. Gish, MD

Professor of Medicine
Loma Linda University
Loma Linda, California
Adjunct Professor of Medicine
Nevada School of Medicine
Las Vega, Nevada
Clinical Professor
University of Nevada Reno School of Medicine
Clinical Professor
University of California Skaggs School of Pharmacy and Pharmaceutical Sciences
San Diego, California
Medical Director

Hepatitis B Foundation
Washington, DC

Robert G. Gish, MD, has disclosed that he has received funds for research support from Gilead Sciences; has received consulting fees from Abbott, AbbVie, Access Biologicals, Antios, Arrowhead, Bayer AG, Bristol-Myers Squibb, Dova, Dynavax, Eiger, Eisai, Enyo, eStudySite, Forty-Seven, Genentech, Genlantis, Gilead Sciences, Hepatx, HepQuant, Intercept, Janssen, Helios, Lilly, Merck, Salix, Shionogi, and Viking; has served on advisory boards for Abbott, AbbVie, Antios, Arrowhead, Bayer, BioCollections, Dova, Eiger, Enyo, Fibronostics, Fujifilm/Wako, Gilead Sciences, HepQuant, Intercept, Janssen, Merck, Prodigy, and Topography Health; and has served on data and safety monitoring boards for Altimmune, Arrowhead, and CymaBay.

Program Medium

This program has been made available online.

Related Content

Patient perspectives and key action items to address in clinical settings to reduce HBV care barriers in the United States, from Clinical Care Options (CCO)

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD Jennifer Wild, MS, BSN, RN, OCN Released: June 22, 2022

Clinical Care Options (CCO) commentary from Dr Carla Coffin on risks vs benefits of treating patients in the indeterminate category for HBV treatment

person default Carla Coffin, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: June 21, 2022 Expired: June 20, 2023

Clinical Care Options (CCO) expert audio: Dr Pietro Lampertico discusses the importance of continued HBV monitoring in patients without indications for immediate treatment

person default Pietro Lampertico, MD, PhD Released: May 26, 2022

Dr Norah Terrault: missed opportunities for hepatitis delta virus (HDV) testing and how to overcome them, from Clinical Care Options (CCO)

Norah Terrault Headshot Norah Terrault, MD, MPH Released: May 18, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings